Copyright: ©Author(s) 2026.
World J Clin Oncol. Mar 24, 2026; 17(3): 113226
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.113226
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.113226
Table 4 Current business case for hospital investment in artificial intelligence-interventional oncology platforms
| Strengths of AI | Supporting claim |
| Clinical efficacy & cost savings | Reduced procedure time |
| Fewer complications with better precision | |
| Optimized resource use | |
| Cost savings | |
| Improved outcomes & quality metrics | Higher technical success rates |
| Personalized treatment | |
| Better documentation | |
| Strategic positioning & innovation | Competitive differentiation |
| Academic and research value | |
| Patient experience | |
| Scalability & long-term ROI | Data-driven learning systems |
| Alignment with value-based care models |
- Citation: Almashni SY, Fayek FB, Javens DC, Boulis MT, Makary MS. Evolving and novel applications of artificial intelligence in interventional oncology. World J Clin Oncol 2026; 17(3): 113226
- URL: https://www.wjgnet.com/2218-4333/full/v17/i3/113226.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i3.113226